Agreement 18: Precision Oncology Genome-Guided Therapy Program

Parties: GenomicTx Corporation and Japanese National Cancer Center **Country**: Japan **Disease Area**: Advanced Solid Tumors with Targetable Mutations **Agreement Overview**: This cutting-edge precision medicine agreement addresses the complex landscape of genomically-targeted cancer therapies. Focusing on approximately 1,200 patients annually with advanced solid tumors harboring actionable mutations, this contract creates a sustainable access model for expensive targeted therapies while generating valuable real-world evidence. The agreement incorporates comprehensive genomic profiling, biomarker-guided treatment selection, and outcomes tracking to optimize personalized cancer care.

Financial Structure:

- Comprehensive genomic profiling: ¥380,000 per patient (>500 cancer-related genes)
- Targeted therapy provision: Treatment-specific pricing with outcome-based components
    - Initial payment: 40% of therapy cost upon treatment initiation
    - Response payment: 30% upon achieving objective response at first assessment
    - Duration payment: 30% for maintaining response for ≥6 months
- Non-responder clause: 50% refund if disease progression occurs within 60 days
- Indication-specific pricing:
    - Tier 1 mutations (strong clinical evidence): ¥1,250,000 per treatment course
    - Tier 2 mutations (moderate evidence): ¥980,000 per treatment course
    - Tier 3 mutations (emerging evidence): ¥750,000 per treatment course
- Patient registry funding: ¥135 million annually for data infrastructure and analysis
- Portfolio approach: Cross-subsidization between highly effective and less effective indications
- Annual cap: Maximum program expenditure of ¥2.8 billion with risk-sharing mechanism
- Real-world evidence generation: ¥85 million research fund with publication requirements

Duration: 3 years with annual portfolio evaluation **Special Provisions**:

- Centralized molecular tumor board for treatment recommendations
- Standardized specimen handling and testing protocols
- Digital pathology infrastructure for remote consultation
- Regular reassessment of genomic classification based on emerging evidence
- Patient identification algorithm using electronic health record
- Biospecimen banking for future research
- Liquid biopsy monitoring for resistance mutations
- Treatment modification protocol based on tumor evolution

- Clinical trial matching service for patients without standard options
- International expert consultation network for rare mutations